Hemostemix plans up to $1 million private placement

By AI, Created 7:15 PM UTC, May 21, 2026, /AGP/ – Hemostemix said it is raising up to $1 million in a non-brokered private placement through the sale of up to 20 million units at 5 cents each. The financing would fund regulatory work in the Bahamas, ACP-01 production, commercialization efforts and working capital.

Why it matters: - The financing gives Hemostemix a new capital source as it works on regulatory submissions, manufacturing and commercialization for ACP-01. - The deal also includes warrants, which could add future funding if exercised. - The company said certain directors may participate, which would make part of the financing a related party transaction under Canadian rules.

What happened: - Hemostemix said it is closing up to $1,000,000 of financing in tranches through a non-brokered private placement. - The offering covers up to 20 million units priced at $0.05 each. - Each unit includes one common share and one-half of one common share purchase warrant. - Two half-warrants make one whole warrant. - Each whole warrant lets the holder buy one common share at $0.12 for 24 months after the offering closes. - Hemostemix trades on the TSX Venture Exchange under HEM, on OTCQB under HMTXF and on the Frankfurt exchange under 2VF0.

The details: - The company can accelerate warrant expiry if, after four months and one day from closing, the common share trades at or above $0.15 for 10 consecutive trading days on the TSX Venture Exchange. - In that case, Hemostemix may issue a press release that moves the expiry date to 30 days after the announcement. - Hemostemix said it is relying on MI 61-101 exemptions from formal valuation and minority shareholder approval requirements. - The company said those exemptions apply because it is not listed on a specified stock exchange and because the related-party portion of the transaction does not exceed 25% of market capitalization. - Securities sold in the private placement will carry a four-month hold period under Canadian securities laws. - The company said the financing proceeds will support regulatory and filing fees tied to submissions to the Ministry of Health and Wellness of the Commonwealth of The Bahamas and related Longevity and Regenerative Therapy Act review processes. - The proceeds will also fund production and manufacturing costs for ACP-01 treatments, plus sales, marketing, patient acquisition, physician education, commercialization, general working capital and corporate purposes. - Hemostemix described itself as an autologous stem cell therapy platform company founded in 2003. - The company said it has developed and patented VesCell, also known as ACP-01. - Hemostemix said ACP-01 is an investigational autologous stem cell therapy derived from a patient’s own blood and aimed at supporting circulation in areas affected by ischemic disease. - The company said it has completed seven clinical studies involving 318 subjects and published results in 11 peer-reviewed papers. - Hemostemix said ACP-01 has shown clinical relevance in peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. - The company said it completed a Phase II trial for chronic limb threatening ischemia and published the results in the Journal of Biomedical Research & Environmental Science. - Hemostemix also said UBC and the University of Toronto reported 0% mortality, pain cessation and wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result, compared with a five-year mortality rate of 50% in the CLTI patient population.

Between the lines: - The use of a non-brokered structure suggests Hemostemix is trying to raise capital with lower financing costs than a marketed deal. - The warrant acceleration feature gives the company a path to clear the overhang faster if the share price rises. - The regulatory and clinical background in the release shows Hemostemix is still positioning ACP-01 as both a medical and commercialization story.

What’s next: - Hemostemix will close the financing in tranches as funds come in. - Any director participation would need to be treated as a related party transaction under MI 61-101. - The company will continue filing and regulatory work tied to Bahamas health ministry review processes while advancing ACP-01 production and commercialization.